SOPHiA GENETICS (SOPH) CSO receives RSU and option grants

Rhea-AI Filing Summary

Chief Scientific Officer Zhenyu Xu received new equity awards from SOPHiA GENETICS SA. On April 2, 2026, he was granted 112,936 ordinary shares as restricted stock units and a share option for 164,671 ordinary shares with a $5.04 exercise price.

The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. These are compensation-related grants rather than open-market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Xu Zhenyu

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	164,671	$0.00	--
Grant/Award	Ordinary Shares	112,936	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 164,671 shares (Direct); Ordinary Shares — 112,936 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

RSU grant: 112,936 shares Option grant size: 164,671 shares Option exercise price: $5.04 per share +4 more

7 metrics

RSU grant 112,936 shares Restricted stock units granted April 2, 2026

Option grant size 164,671 shares Share option granted April 2, 2026

Option exercise price $5.04 per share Exercise price for option on 164,671 shares

RSU initial vesting 25% RSUs vest 25% on April 2, 2027

RSU remaining vesting 75% RSUs vest quarterly through April 2, 2030

Option vesting start 25% Option vests 25% on April 2, 2027

Option expiration April 2, 2036 Expiration date of share option grant

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vesting, exercise price, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

vesting financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price": "5.0400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

share option financial

"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/02/2026		A		112,936(1)	A	$0	112,936	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.04	04/02/2026		A		164,671		(2)	04/02/2036	Ordinary Shares	164,671	$0	164,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did SOPHiA GENETICS (SOPH) report for Zhenyu Xu?

SOPHiA GENETICS reported that Chief Scientific Officer Zhenyu Xu received equity awards on April 2, 2026: 112,936 ordinary shares as restricted stock units and a share option for 164,671 ordinary shares as part of his compensation package.

How many RSUs did SOPHiA GENETICS grant to Zhenyu Xu on April 2, 2026?

He received 112,936 restricted stock units (RSUs) on April 2, 2026. Each RSU represents a contingent right to one ordinary share, subject to continued service and a vesting schedule running from April 2, 2027 through April 2, 2030.

What are the terms of Zhenyu Xu’s share option grant at SOPHiA GENETICS?

He received a share option for 164,671 ordinary shares with a $5.04 exercise price. The option vests 25% on April 2, 2027, with the rest vesting in equal monthly installments through April 2, 2030, and expires on April 2, 2036.

How do Zhenyu Xu’s RSUs at SOPHiA GENETICS vest over time?

The 112,936 RSUs vest based on continued service. 25% vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, aligning long-term incentives with ongoing employment.

Are Zhenyu Xu’s SOPHiA GENETICS equity awards open-market purchases or compensation grants?

They are compensation-related grants, not open-market purchases. Both the RSUs and the share option were granted at a $0.00 grant price under the company’s 2021 Equity Incentive Plan, with vesting tied to his continued service.

How many SOPHiA GENETICS shares and options does Zhenyu Xu hold after these grants?

Following these awards, he directly holds 112,936 ordinary shares from RSUs and a share option for 164,671 ordinary shares. These positions are subject to the described vesting schedules and, for the option, a $5.04 exercise price.